Literature DB >> 11291045

Up-regulation of vaults may be necessary but not sufficient for multidrug resistance.

A C Siva1, S Raval-Fernandes, A G Stephen, M J LaFemina, R J Scheper, V A Kickhoefer, L H Rome.   

Abstract

Vaults are ribonucleoprotein complexes comprised of the 100 kDa major vault protein (MVP), the 2 high m.w. vault proteins p193 (VPARP) and p240 (TEP1) and an untranslated small RNA (vRNA). Increased levels of MVP, vault-associated vRNA and vaults have been linked directly to non-P-glycoprotein-mediated multidrug resistance (MDR). To further characterize the putative role of vaults in MDR, expression levels of all of the vault proteins were examined in various MDR cell lines. Subcellular fractionation of vault particles revealed that all 3 vault proteins are increased in MDR cells compared to the parental, drug-sensitive cells. Furthermore, protein analysis of subcellular fractions of the drug-sensitive, MVP-transfected AC16 cancer cell line indicated that vault levels are increased, in this stable line. Since TEP1 is shared by both vaults and the telomerase complex, TEP1 protein (and vault) levels were compared with telomerase activity in a variety of cell lines, including various MDR lines. Our studies demonstrate that while vault levels may be a good predictor of drug resistance, their up-regulation alone is not sufficient to confer the drug-resistant phenotype. This implies a requirement of an additional factor(s) for vault-mediated MDR. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11291045     DOI: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1168>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Engineering of vault nanocapsules with enzymatic and fluorescent properties.

Authors:  Valerie A Kickhoefer; Yvette Garcia; Yeshi Mikyas; Erik Johansson; Jing C Zhou; Sujna Raval-Fernandes; Payam Minoofar; Jeffrey I Zink; Bruce Dunn; Phoebe L Stewart; Leonard H Rome
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 3.  Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy.

Authors:  Ana Carolina Rabello de Moraes; Caroline Klein Maranho; Gabriela Schneider Rauber; Maria Cláudia Santos-Silva
Journal:  J Clin Lab Anal       Date:  2013-01-04       Impact factor: 2.352

4.  Vaults are dynamically unconstrained cytoplasmic nanoparticles capable of half vault exchange.

Authors:  Jian Yang; Valerie A Kickhoefer; Benny C Ng; Ajaykumar Gopal; Laurent A Bentolila; Scott John; Sarah H Tolbert; Leonard H Rome
Journal:  ACS Nano       Date:  2010-12-01       Impact factor: 15.881

5.  iTRAQ quantitative analysis of multidrug resistance mechanisms in human gastric cancer cells.

Authors:  Huai-Dong Hu; Feng Ye; Da-Zhi Zhang; Peng Hu; Hong Ren; Sang-Lin Li
Journal:  J Biomed Biotechnol       Date:  2010-06-06

6.  Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression.

Authors:  Pedro C Lara; Marta Lloret; Bernardino Clavo; Rosa M Apolinario; Luis Alberto Henríquez-Hernández; Elisa Bordón; Fausto Fontes; Agustín Rey
Journal:  Radiat Oncol       Date:  2009-08-06       Impact factor: 3.481

7.  Unimpaired dendritic cell functions in MVP/LRP knockout mice.

Authors:  Marieke H Mossink; Jan de Groot; Arend van Zon; Erna Fränzel-Luiten; Martijn Schoester; George L Scheffer; Pieter Sonneveld; Rik J Scheper; Erik A C Wiemer
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

8.  Targeting vault nanoparticles to specific cell surface receptors.

Authors:  Valerie A Kickhoefer; Muri Han; Sujna Raval-Fernandes; Michael J Poderycki; Raymond J Moniz; Dana Vaccari; Mariena Silvestry; Phoebe L Stewart; Kathleen A Kelly; Leonard H Rome
Journal:  ACS Nano       Date:  2009-01-27       Impact factor: 15.881

9.  Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).

Authors:  Lei Lou; Juan Wang; Fengzhu Lv; Guohui Wang; Yuehong Li; Lingxiao Xing; Haitao Shen; Xianghong Zhang
Journal:  Cell Oncol (Dordr)       Date:  2020-09-07       Impact factor: 6.730

10.  Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer.

Authors:  Ya-Nan Zhao; Dong-Ning He; Ya-DI Wang; Jun-Jie Li; Min-Wen Ha
Journal:  Oncol Lett       Date:  2016-03-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.